WO2004041296A3 - Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides - Google Patents

Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides Download PDF

Info

Publication number
WO2004041296A3
WO2004041296A3 PCT/DK2003/000752 DK0300752W WO2004041296A3 WO 2004041296 A3 WO2004041296 A3 WO 2004041296A3 DK 0300752 W DK0300752 W DK 0300752W WO 2004041296 A3 WO2004041296 A3 WO 2004041296A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polypeptides
pharmaceutical composition
tissue factor
factor antagonist
Prior art date
Application number
PCT/DK2003/000752
Other languages
French (fr)
Other versions
WO2004041296A2 (en
Inventor
Lars Christian Petersen
Jakob Michael Back
Christian Meyer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to AU2003275948A priority Critical patent/AU2003275948A1/en
Publication of WO2004041296A2 publication Critical patent/WO2004041296A2/en
Publication of WO2004041296A3 publication Critical patent/WO2004041296A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition comprising a TF antagonist and protein C or a protein C-related polypeptide, and the use thereof for treating Thrombotic or Coagulopathic relatedl diseases, Respiratory diseases and Inflammatory diseases.
PCT/DK2003/000752 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides WO2004041296A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003275948A AU2003275948A1 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201709 2002-11-06
DKPA200201709 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004041296A2 WO2004041296A2 (en) 2004-05-21
WO2004041296A3 true WO2004041296A3 (en) 2004-07-29

Family

ID=32309251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000752 WO2004041296A2 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Country Status (2)

Country Link
AU (1) AU2003275948A1 (en)
WO (1) WO2004041296A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516564A (en) * 2003-01-22 2006-07-06 ノボ　ノルディスク　アクティーゼルスカブ TF binding agents and their use
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
US9168314B2 (en) 2010-06-15 2015-10-27 Genmab A/S Human antibody drug conjugates against tissue factor
US20150150954A1 (en) * 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] June 1998 (1998-06-01), HOLST J ET AL: "Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.", XP002281243, Database accession no. NLM9659887 *
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY: THE OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR VASCULAR SURGERY. ENGLAND JUN 1998, vol. 15, no. 6, June 1998 (1998-06-01), pages 515 - 520, ISSN: 1078-5884 *
JOYCE C.Y. CHAN ET AL: "Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 7, April 2000 (2000-04-01), pages 897 - 903, XP002281241 *
LEONARD PRESTA ET AL: "Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeuctic", THROMB HACMOST, vol. 85, 2001, pages 379 - 389, XP002281242 *

Also Published As

Publication number Publication date
WO2004041296A2 (en) 2004-05-21
AU2003275948A8 (en) 2004-06-07
AU2003275948A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
AU2003223497A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
EP1578930A4 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2006056987A3 (en) Leptin antagonists
WO2004071382A3 (en) Substituted heterocycles
WO2006114805A3 (en) Use of hmgb2 and hmgb3 proteins for medical applications
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2005097826A3 (en) Prokineticin 2beta peptide and its use
WO2005086825A3 (en) Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion
IL207422A0 (en) Improved recombinant human interferon-beta-ib polypeptides
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2004041296A3 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
EP1808179A3 (en) Use of HSP20 for promoting wound healing and/or reducing scar formation
WO2002072769A3 (en) Human serpin polypeptides
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO2003074656A3 (en) Rank-ligand-induced sodium/proton antiporter polypeptides
WO2003100001A3 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
WO2005019825A3 (en) Secreted polypeptide species and use thereof
WO2004089302A3 (en) Posh polypeptides, complexes and related methods
WO2004039961A3 (en) Trefoil domain-containing polypeptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP